Key Takeaways
- Revenue surged 32% YoY, but the base was soft: Growth was powered by Pharma, Polymer and Tanfac, while Agrochem remained a drag after the loss of a large domestic MNC contract that historically contributed ~15% of revenues.
- Margins hit 31% EBITDA on mix and cost control: A favorable product mix, strong Tanfac margins, and a double-digit drop in standalone overheads and manpower costs (lower ESOP, less job work) lifted profitability.
- The balance sheet is carrying the scars of a long slowdown: Inventory ballooned as production continued while sales degrew for 18 months, and receivables stretched because customers were given extra credit in a slow market. Management calls this a “double whammy” that reverses only when growth returns.
- FY26 is framed as the breakout year: Management targets 30–35% revenue growth, with the bulk of the INR10,700 cr order book commercializing, new US contracts kicking in, and Agrochem recovering.
- What to watch next quarter: Whether the promised Q4 Agrochem recovery materializes, the pace of inventory and receivable normalization as growth resumes, and any concrete progress on the 180–200 day working capital target.
The Agrochem Reset
- The 15% hole: One large Indian MNC agrochem customer, contributing around 15% of total revenues, was withdrawn from. The process started in FY24 and the full impact is visible in FY25, making it the single largest reason for the segment’s weakness.
- Europe added to the pain: Beyond the contract loss, agrochem demand from Europe stayed weak for nine months, compounding the drag.
- Recovery signal: Management expects a stronger agrochem number in Q4 and into FY26, though no specific quantum was given.
Vishal Thakkar: “I appreciate this is a matter of concern for each of us. The only thing that I can say is the reflective will be when I get my sales back -- sales growth back because sales is there, but it's not sufficient enough.”
Order Book & Commercialization Pipeline
- INR10,700 cr order book, INR3,100 cr already live: The remaining majority is slated for commercialization in FY26, which underpins the 30–35% growth target.
- LOI conversion accelerating: 20–25% of FY25 revenue is expected from LOIs and contracts, with FY26 pegged as a “significantly higher number.” Peak revenue from the current LOI pipeline is targeted by FY28.
- US entry gains traction: One contract and one LOI signed with a US MNC for high-performance specialty chemicals in defense, electronics and aerospace. Both are expected to commercialize within the next year and contribute meaningfully. The US as an end-market is projected to reach the high teens percentage of sales in 12–18 months.
- Japan looms large: Japan is expected to contribute roughly one-third of sales over the next 2–3 years, with most business secured under long-term contracts.
Margins: The 31% Print and the 26–28% Guide
- What drove the beat: A couple of high-margin products shipped in the quarter, plus Tanfac’s strong contribution and a double-digit decline in standalone overheads (lower ESOP, reduced job-work outsourcing on lower volumes).
- Why guidance stays at 26–28%: Management flags two structural headwinds as new plants ramp: initial overhead absorption pressure and a learning curve on newer products. The 31% is treated as a quarterly mix benefit, not a new baseline.
- Pharma and Polymer bias upward: Both segments carry an upward margin bias due to niche applications, especially in polymer, which supports pricing power. The goal is a balanced portfolio-level EBITDA margin.
Vishal Thakkar: “Both on polymer and pharma, we should have an upward bias on margins. And these are very niche applications, especially in polymer, which will ensure that our ability to ask for and maintain that margin should be there.”
Working Capital: The Overhang
- Inventory is structural and cyclical: 80% of working capital sits in finished goods and WIP, not raw material. When growth was expected, production plans were set; 18 months of degrowth meant sales did not clear that output, creating a “double whammy” of accumulation. Management argues inventory should be measured against sales, not COGS.
- Receivables stretched in the slowdown: Debtors expanded over the last 4–6 quarters as additional credit was extended to customers under pressure, including a large tech-chem company that requested a payment delay.
- Pharma vs. Agro dynamics: Pharma (largely Indian customers) carries higher receivable days due to longer domestic payment cycles but requires less inventory, so the mix roughly evens out.
- Target and timeline: 180–200 net working capital days is the goal, achievable in 18–24 months. Management expects strong EBITDA-to-operating-cash-flow conversion once growth resumes and days reduce.
- Debt guidance withheld: When asked for a gross debt figure in two years, management declined to provide guidance. INR270 cr from promoter warrants in Q1 FY26 is earmarked primarily for debt reduction.
Vishal Thakkar: “I believe that the moment we start achieving the growth and the reduction in the working capital days, there will be a very strong conversion of EBITDA to operating cash flows.”
Capex & Capacity
- INR650 cr of INR670 cr capex complete: All plants are on track for commercialization by March 31, 2025. Total cash outflow for the year is INR200 cr, with INR670 cr gross block added by year-end.
- Capacity up 3,000 tonnes to 30,000: Expansion split across Sachin (Units 5 and 6, ~1,200 tonnes) and Jhagadia (balance).
- Green energy commissioned: A INR59 cr, 9.2 MW hybrid solar and green energy plant went live in October 2024, targeting 65% of electricity needs from green sources going forward.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 30–35% YoY increase (standalone basis) | FY26 |
| Order book commercialization | Majority of remaining INR10,700 cr order book (INR3,100 cr already live) to be commercialized | FY26 |
| US end-market share | High teens percentage of sales | 12–18 months (by end of next year) |
| Japan contribution | Approximately one-third of sales | 2–3 years |
| LOI pipeline peak revenue | Large part of peak revenue from current LOI pipeline | By FY28 |
| New US contracts | Both new US contracts (one signed, one LOI) to be commercialized with significant revenue addition | Next year (FY26) |
| Working capital days | 180–200 days | 18–24 months |
| Green energy share | 65% of electricity needs met through green energy | Future (no specific date) |
| Promoter warrant proceeds | INR270 cr primarily for debt reduction | Q1 FY26 |
| Q4 FY25 revenue | ~15% growth QoQ to achieve mid-teens full-year decline | Q4 FY25 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Operating revenue (consolidated) | ₹390 cr, +32% YoY and +33% QoQ |
| EBITDA including other income | ₹121 cr, +48% YoY |
| EBITDA margin | 31%, up 389 bps YoY |
| Profit after tax | ₹54 cr, +108% YoY |
| 9M FY25 operating revenue | ₹938 cr, -13% YoY |
| 9M FY25 EBITDA margin | 28% |
| 9M FY25 PAT | ₹97 cr, vs ₹127 cr in 9M FY24 |
| FY26 revenue growth target | 30% to 35% on standalone basis |
| FY25 full-year revenue growth | Mid-teens degrowth on standalone basis |
| Order book | ₹10,700 cr, spread over 5–6 years; ₹3,100 cr already commercialized |
| Revenue from LOIs and contracts | 20% to 25% of FY25 revenue |
| Agrochem share of revenue | 50%–55% in 9M FY25 |
| Top 10 customer concentration | 63% of total revenue |
| Gross debt | ₹1,200 cr as of Dec 31, 2024, vs ₹1,270 cr as of Sep 30, 2024 |
| Capex completed (of planned ₹670 cr) | ₹650 cr as of Dec 31, 2024 |
| Capacity | 30,000 tons, up from 27,000 tons |